Description Angiotech Pharmaceuticals is teaching old devices new tricks. It develops medical products that combine devices with drugs to make them more effective. Its flagship product in the Pharmaceutical Technologies segment is the TAXUS drug-eluting stent, which Boston Scientific sells and for which it pays Angiotech royalties. The company's Medical Products segment makes the Quill wound closure system and other single-use medical products for interventional radiology, ophthalmology, and surgery. Angiotech received bankruptcy protection from its creditors under Canada's Companies' Creditors Arrangement Act.
Angiotech Pharmaceuticals has an employee rating of 3.0 out of 5 stars, based on 17 company reviews on Glassdoor which indicates that most employees have an average working experience there. The Angiotech Pharmaceuticals employee rating is in line with the average (within 1 standard deviation) for employers within the Manufacturing industry (3.5 stars).
Overall, 7% of employees would recommend working at Angiotech Pharmaceuticals to a friend. This is based on 17 anonymously submitted reviews on Glassdoor.
100% of job seekers rate their interview experience at Angiotech Pharmaceuticals as positive. Candidates give an average difficulty score of 3 out of 5 (where 5 is the highest level of difficulty) for their job interview at Angiotech Pharmaceuticals.